Market Intelligence, Clinical Progress, and High-Purity Reagents for Leber Congenital Amaurosis (LCA10), Joubert Syndrome, and Related Ciliopathy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CEP290 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CEP290 Domain Proteins (CC1-CC13, SMC, KID) and Mutant Variants (C998*). High purity (>95%), Endotoxin <1 EU/µg. Sequence verified by Mass Spec. | View CEP290 Products |
| Gene Delivery | CEP290 Codon-Optimized Lentivirus (full-length ORF or minigene splice-reporter) for stable cell lines in hTERT-RPE1/IMCD3 ciliated models. | View CEP290 Products |
| Benchmark Ab | Anti-CEP290 (Research-Grade Recombinant Monoclonal) – validated for IF, WB, IHC. Sequence-verified. | View CEP290 Products |
| Validator | CEP290 siRNA Set for knockdown verification and specificity controls (endotoxin-controlled for primary cells). | View CEP290 Products |
| Related Target A | NPHP5 (IQCB1) – forms functional complex with CEP290 at the ciliary transition zone; critical for Senior-Løken syndrome synergy assays. | View NPHP5 Products |
| Related Target B | RPGR – interacts with CEP290 at photoreceptor connecting cilium; essential for retinal degenerative disease co-studies. | View RPGR Products |
| Related Target C | RPGRIP1 – retinal ciliopathy network; critical for photoreceptor outer segment maintenance. | View RPGRIP1 Products |
| Related Target D | CEP164 – interacting partner in primary cilia formation; used for parallel ciliogenesis controls. | View CEP164 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length CEP290 (~290 kDa) is refractory to recombinant expression | Modular domain fragments (CC1-CC13, SMC, KID) with >95% purity, endotoxin <1 EU/µg, and theoretical MW verified by Mass Spec |
| Transition-zone conformation requires native intracellular context | HEK293-expressed lentivirus for stable ciliated cell lines preserving basal body and centriolar architecture |
| Cryptic exon splicing mutations (e.g., c.2991+1655A>G in LCA10) | Codon-optimized minigene reporter lentivirus with intron 26 for ASO/CRISPR splice-correction screening |
| Off-target antibody binding in centriolar proteome | Validated siRNA set for knockdown specificity confirmation; recombinant benchmark antibodies included for assay standardization |
Live CEP290 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CEP290 therapeutics is intensifying, dominated by antisense oligonucleotide (ASO) and gene editing modalities. ProQR’s Sepofarsen (ASO targeting c.2991+1655A>G) advanced to Phase 3 (ILLUMINATE), though FDA requested additional efficacy data, creating a window for competitors. Editas Medicine’s EDIT-101 (CRISPR/Cas9) was halted in 2023, highlighting in vivo editing challenges. Next-wave R&D focuses on dual-AAV minigene delivery (split-intein or overlapping strategies), mutation-agnostic small-molecule read-through agents, and expanded genetic testing for broader CEP290-related disease portfolios (Joubert, Senior-Løken). Key bottlenecks include ocular delivery (subretinal vs. intravitreal) and long-term safety monitoring for off-target edits or splicing adaptation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO (Splice Switching) | ProQR Therapeutics | LCA10 (c.2991+1655A>G) | Minigene splicing assay with reporter lentivirus for ASO screening |
| CRISPR/Cas9 Gene Editing | Editas Medicine | LCA10 | Editing efficiency validation using stable cell lines and mutant/WT protein controls |
| AAV Gene Therapy (Minigene) | AGTC, AbbVie, Academic Consortia | LCA, Retinal Dystrophy, Joubert Syndrome | Dual-vector systems; need domain-truncated protein controls (<4.7 kb) for expression validation |
| Small Molecule (Read-through) | Academic Consortia | Nonsense mutations (e.g., C998*) | Read-through assay with mutant (C998*) vs. WT protein pairs for HTS |